About Idenix Pharmaceuticals (NASDAQ:IDIX)
Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Idenix Pharmaceuticals (NASDAQ:IDIX) Frequently Asked Questions
What is Idenix Pharmaceuticals' stock symbol?
Idenix Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDIX."
Who are some of Idenix Pharmaceuticals' key competitors?
Some companies that are related to Idenix Pharmaceuticals include Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Microsoft (MSFT), Amazon.com (AMZN), Facebook (FB), Intel (INTC), Cisco Systems (CSCO), PepsiCo (PEP), Comcast (CMCSA), Netflix (NFLX), Nvidia (NVDA), Amgen (AMGN), Adobe Systems (ADBE), Booking (BKNG), Texas Instruments (TXN), Broadcom (AVGO) and Gilead Sciences (GILD).
Has Idenix Pharmaceuticals been receiving favorable news coverage?
News headlines about IDIX stock have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Idenix Pharmaceuticals earned a daily sentiment score of 0.17 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 45.71 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Idenix Pharmaceuticals?
Shares of IDIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Idenix Pharmaceuticals?
Idenix Pharmaceuticals' mailing address is 320 Bent St, CAMBRIDGE, MA 02141-2025, United States. The biopharmaceutical company can be reached via phone at +1-617-9959800.
MarketBeat Community Rating for Idenix Pharmaceuticals (IDIX)MarketBeat's community ratings are surveys of what our community members think about Idenix Pharmaceuticals and other stocks. Vote "Outperform" if you believe IDIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Idenix Pharmaceuticals (NASDAQ:IDIX) Analyst Ratings History
(Data available from 4/20/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Idenix Pharmaceuticals (NASDAQ:IDIX) Earnings History and Estimates Chart
Idenix Pharmaceuticals (NASDAQ IDIX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/1/2014||Q114||($0.19)||($0.24)||$0.22 million||($3.01) million||View||N/A|
|2/27/2014||Q413||($0.22)||($0.21)||$0.15 million||$0.50 million||View||N/A|
|10/30/2013||Q3 2013||($0.21)||($0.25)||$2.13 million||$0.02 million||View||N/A|
|8/7/2013||Q2 2013||($0.23)||($0.22)||$0.30 million||$0.11 million||View||N/A|
|4/30/2013||Q1 2013||($0.18)||($0.23)||$0.33 million||$0.85 million||View||N/A|
|2/25/2013||Q412||($0.17)||($0.17)||$0.74 million||$0.3270 million||View||N/A|
|11/1/2012||Q312||($0.17)||$0.03||$2.60 million||$32.30 million||View||N/A|
Idenix Pharmaceuticals (NASDAQ:IDIX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Idenix Pharmaceuticals (NASDAQ IDIX) Insider Trading and Institutional Ownership History
Idenix Pharmaceuticals (NASDAQ IDIX) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/31/2014||Baupost Group Llc/Ma||major shareholder||Buy||16,420,241||$6.50||$106,731,566.50|| |
Idenix Pharmaceuticals (NASDAQ IDIX) News Headlines
Idenix Pharmaceuticals (NASDAQ:IDIX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Idenix Pharmaceuticals (NASDAQ:IDIX) Income Statement, Balance Sheet and Cash Flow Statement
Idenix Pharmaceuticals (NASDAQ IDIX) Stock Chart for Friday, April, 20, 2018